Poly Medicure Ltd

Q1 FY27, unaudited

Revenue: ₹525.38 Cr
Profit after tax: ₹85.27 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ crore	Q1 FY27	vs a year ago	FY26
Revenue from operations	525.38	+30.30%	1,875.26
Other income	33.41	−19.87%	120.08
Total income	558.78	+25.60%	1,995.34
Employee benefit expense	126.90	+68.95%	402.26
Finance costs	6.50	+120.38%	18.29
Depreciation & amortisation	36.25	+55.88%	115.52
Total expenses	443.03	+37.04%	1,566.75
Profit before tax	115.75	−4.83%	421.79
Tax expense	32.03	+7.26%	106.74
Profit after tax	85.27	−8.39%	320.73
Total comprehensive income	85.23	−7.75%	367.22

Earnings per share
Earnings per share, basic	₹8.49	₹31.79
Earnings per share, diluted	₹8.48	₹31.75

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

Poly Medicure reported FY26 standalone revenue of around Rs 1,662 crore, up about 4%, and consolidated revenue of Rs 1,875 crore, up 12.3%, with standalone EBITDA margin of 26.8%. Management described FY26 as a year of transition toward high-technology segments, including the acquisitions of PendraCare, Citieffe, and Medyneo in Brazil. The company guided FY27 consolidated revenue of Rs 2,300-2,400 crore and standalone revenue of Rs 1,900-1,950 crore, while flagging raw material cost pressure and Gulf-region shipping disruptions.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 58 published by the exchange

22 Aug 2026
Concall
Intimation For The Schedule Of Investors/Analysts Call/Meet.
20 Aug 2026
Concall
Investors Call Scheduled To Be Held On 20 August, 2026 Is Cancelled - Updates On Call
17 Aug 2026
Concall
Intimation For The Schedule Of Investors/Analysts Call/Meet.
15 Aug 2026
Filing
Newspaper Publication
14 Aug 2026
Transcript
Analyst Investor Meet Call Transcript
14 Aug 2026
Filing
Annual Report 2025-26
14 Aug 2026
Dividend
Record Date/Cut-Off Date For The Dividend Purpose
14 Aug 2026
Dividend
Dividend Updates
14 Aug 2026
Dividend
Book Closure For The Purpose Of Record Date For The Purpose Of Dividend
14 Aug 2026
Filing
Intimation Of Dispatch Of Letter To Shareholder Whose Email Address Are Not Registered With Company And Depository
14 Aug 2026
Filing
Business Responsibility and Sustainability Reporting (BRSR)
14 Aug 2026
Filing
31ST Annual General Meeting To Be Held On September 05Th, 2026

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 22 Aug 2026.